Read the anns 06/12/23
This trial is not sponsored by IMU and not under IMU's control. The Uni London has chosen PD1-Vaxx over Keytruda. Could be because of costs or, as they said, the superior properties of PD1-Vaxx.
Again, market gives a damn, but the scientists approve it.
Investors follow the sp, scientists follow the science. Who will get it right in the end?
GLTA
Read the anns 06/12/23This trial is not sponsored by IMU and not...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.2M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $1.098M | 21.50M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 97 | 7481668 | 5.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.1¢ | 1703097 | 4 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |